Nanotechnology Community

what are design considerations and biological barriers that must be addressed when developing targeted nanotechnology-based drug delivery systems for systemic administration.

------------------------------
Kabirat Babalola
Ph.D Student
The University of Alabama
Tuscaloosa AL
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------

Hello Kabirat,

When developing targeted nanotechnology-based drug delivery systems for systemic administration, several design considerations and biological barriers must be addressed:

Design Considerations:

• Particle size and surface charge: Optimized to enhance circulation time, avoid rapid clearance, and promote tissue penetration.

• Surface modification: Addition of polymers like PEG (PEGylation) to improve stability and evade immune detection (stealth properties).

• Targeting ligands: Incorporation of antibodies, peptides, or small molecules to achieve active targeting to specific cells or tissues.

• Drug loading and release profile: Ensuring high drug loading efficiency and controlled, sustained release at the target site.

• Biocompatibility and biodegradability: Materials must be non-toxic and safely metabolized or excreted.

• Scalability and reproducibility: Formulations should be feasible for large-scale, consistent production.

Biological Barriers:

• Mononuclear phagocyte system (MPS): Nanoparticles are often cleared by macrophages in the liver and spleen.

• Vascular endothelium: Crossing tight endothelial barriers, especially in solid tumors or the brain (blood-brain barrier), is challenging.

• Blood circulation: Shear forces and protein corona formation can alter nanoparticle properties and targeting ability.

• Tumor microenvironment: High interstitial pressure, dense extracellular matrix, and abnormal vasculature can impede nanoparticle delivery.

• Cellular uptake and intracellular trafficking: Nanoparticles must efficiently enter target cells and release their payload at the right intracellular location.

Addressing design considerations and overcoming biological barriers is critical for the success of nanotechnology-based drug delivery systems intended for systemic administration. Thoughtful design enhances the efficacy, safety, and specificity of therapies by ensuring that drugs are delivered precisely to the target tissue while minimizing off-target effects and toxicity.

By navigating biological barriers such as immune clearance, vascular transport, and cellular uptake, these systems can improve bioavailability, prolong circulation time, enhance therapeutic outcomes, and reduce side effects compared to conventional therapies. This leads to better patient compliance, lower treatment costs, and more effective treatment of challenging diseases such as cancer, neurological disorders, and inflammatory conditions.

Ultimately, successful design and delivery strategies help to bridge the gap between laboratory innovation and clinical translation, advancing personalized medicine and opening new possibilities for treating complex diseases.

------------------------------
Mahavir Chougule PhD
Associate Professor of Pharmaceutical Sciences
Mercer University College of Pharmacy
Atlanta GA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------

Original Message:
Sent: 04-29-2025 10:12
From: Kabirat Babalola
Subject: Let's talk about targeted nanotechnology-based drug delivery systems

what are design considerations and biological barriers that must be addressed when developing targeted nanotechnology-based drug delivery systems for systemic administration.

------------------------------
Kabirat Babalola
Ph.D Student
The University of Alabama
Tuscaloosa AL
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------

The list is long as you can see from the other responses and to prioritize you need to first answer 3 main points:

1. What is the Target Product Profile ?  i.e.  target site, administration route, anticipated dose,  It is always better to start with the "End in Mind".
2. Show efficacy and safety in vivo rather than in vitro.  Doesn't have to be with the final formulation but you need to show feasibility and safety.
3. Back of the envelop calculations on the economics.  Cost of goods, encapsulation efficiency, potential for scale-up (this can be addressed later through technological improvements).

Hope this helps.

Rajiv

------------------------------
Rajiv Nayar Ph.D.
President
HTD Biosystems Inc.
Livermore CA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------

Original Message:
Sent: 04-29-2025 12:53
From: Mahavir Chougule
Subject: Let's talk about targeted nanotechnology-based drug delivery systems

Hello Kabirat,

When developing targeted nanotechnology-based drug delivery systems for systemic administration, several design considerations and biological barriers must be addressed:

Design Considerations:

• Particle size and surface charge: Optimized to enhance circulation time, avoid rapid clearance, and promote tissue penetration.

• Surface modification: Addition of polymers like PEG (PEGylation) to improve stability and evade immune detection (stealth properties).

• Targeting ligands: Incorporation of antibodies, peptides, or small molecules to achieve active targeting to specific cells or tissues.

• Drug loading and release profile: Ensuring high drug loading efficiency and controlled, sustained release at the target site.

• Biocompatibility and biodegradability: Materials must be non-toxic and safely metabolized or excreted.

• Scalability and reproducibility: Formulations should be feasible for large-scale, consistent production.

Biological Barriers:

• Mononuclear phagocyte system (MPS): Nanoparticles are often cleared by macrophages in the liver and spleen.

• Vascular endothelium: Crossing tight endothelial barriers, especially in solid tumors or the brain (blood-brain barrier), is challenging.

• Blood circulation: Shear forces and protein corona formation can alter nanoparticle properties and targeting ability.

• Tumor microenvironment: High interstitial pressure, dense extracellular matrix, and abnormal vasculature can impede nanoparticle delivery.

• Cellular uptake and intracellular trafficking: Nanoparticles must efficiently enter target cells and release their payload at the right intracellular location.

Addressing design considerations and overcoming biological barriers is critical for the success of nanotechnology-based drug delivery systems intended for systemic administration. Thoughtful design enhances the efficacy, safety, and specificity of therapies by ensuring that drugs are delivered precisely to the target tissue while minimizing off-target effects and toxicity.

By navigating biological barriers such as immune clearance, vascular transport, and cellular uptake, these systems can improve bioavailability, prolong circulation time, enhance therapeutic outcomes, and reduce side effects compared to conventional therapies. This leads to better patient compliance, lower treatment costs, and more effective treatment of challenging diseases such as cancer, neurological disorders, and inflammatory conditions.

Ultimately, successful design and delivery strategies help to bridge the gap between laboratory innovation and clinical translation, advancing personalized medicine and opening new possibilities for treating complex diseases.

------------------------------
Mahavir Chougule PhD
Associate Professor of Pharmaceutical Sciences
Mercer University College of Pharmacy
Atlanta GA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.

Original Message:
Sent: 04-29-2025 10:12
From: Kabirat Babalola
Subject: Let's talk about targeted nanotechnology-based drug delivery systems

what are design considerations and biological barriers that must be addressed when developing targeted nanotechnology-based drug delivery systems for systemic administration.

------------------------------
Kabirat Babalola
Ph.D Student
The University of Alabama
Tuscaloosa AL
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------